Overview - The company Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has participated in the establishment of a private equity investment fund named "China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership)" [2] Group 1 - On October 28, 2025, the company signed a partnership agreement with 11 other investors to jointly establish the fund [2] - The fund has completed its registration with the Asset Management Association of China [3] - The fund is managed by Shenzhen China Resources Capital Equity Investment Co., Ltd. and is custodied by China Merchants Bank Co., Ltd. [3]

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]